ArticleNeuroscience2010
Activation of liver X receptor reduces global ischemic brain injury by reduction of nuclear factor-kappaB.
Article in Neuroscience, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 76 citations in OpenAlex.
- ACSL3 is a promising therapeutic target for alleviating anxiety and depression in Alzheimer's disease.GeroScience · 2025Article
- LXR agonism for CNS diseases: promises and challenges.Journal of neuroinflammation · 2024Review
- Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2.Cell death & disease · 2023Article
- MEX3C induces cognitive impairment in mice through autophagy inhibition.Brain and behavior · 2023Article
- Liver X Receptor as a Possible Drug Target for Blood-Brain Barrier Integrity.Advanced pharmaceutical bulletin · 2022Review
- GABAStem cell research & therapy · 2021Article
- Regulatory microRNAs and vascular cognitive impairment and dementia.CNS neuroscience & therapeutics · 2020Review
- Cerebral Ischemia-Reperfusion Injury: Lysophosphatidic Acid Mediates Inflammation by Decreasing the Expression of Liver X Receptor.Journal of molecular neuroscience : MN · 2020Article
- Epigenetic suppression of liver X receptor β in anterior cingulate cortex by HDAC5 drives CFA-induced chronic inflammatory pain.Journal of neuroinflammation · 2019Article
- Role of Liver X Receptor in Mastitis Therapy and Regulation of Milk Fat Synthesis.Journal of mammary gland biology and neoplasia · 2019Review
- Liver X Receptor Alpha Is Important in Maintaining Blood-Brain Barrier Function.Frontiers in immunology · 2019Article
- LXR ligands induce apoptosis of EGFR-TKI-resistant human lung cancer cellsOncology letters · 2018Article
- Genetic Deletion of PGFFrontiers in neuroscience · 2018Article
- Toxic effect of acrylamide on the development of hippocampal neurons of weaning rats.Neural regeneration research · 2017Article
- Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR-TKI treatment.FEBS open bio · 2017Article
- Dissociated sterol-based liver X receptor agonists as therapeutics for chronic inflammatory diseases.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016Article
- Treatment with TO901317, a synthetic liver X receptor agonist, reduces brain damage and attenuates neuroinflammation in experimental intracerebral hemorrhage.Journal of neuroinflammation · 2016Article
- Rifampicin Attenuated Global Cerebral Ischemia Injury via Activating the Nuclear Factor Erythroid 2-Related Factor Pathway.Frontiers in cellular neuroscience · 2016Article
- Emerging role of liver X receptors in cardiac pathophysiology and heart failure.Basic research in cardiology · 2016Review
- Anti-inflammation Effects of Oxysophoridine on Cerebral Ischemia-Reperfusion Injury in Mice.Inflammation · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Recent studies have found that liver X receptors (LXRs) agonists decrease brain inflammation and exert neuroprotective effect. The aim of this study was to examine the mechanisms of action of liver X receptor agonist GW3965 against brain injury following global cerebral ischemia in the rat. The 48 male SD (Sprague-Dawley) rats were randomly partitioned into three groups: sham, global ischemia (4-vessel occlusion for 15 min; 4VO) treated with vehicle and global ischemia treated with GW3965 (20 mg/kg, via i.p. injection at 10 min after reperfusion). The functional outcome was determined by neurological evaluation at 24 h post ischemia and by testing rats in T maze at 3 and 7 days after reperfusion. The rats' daily body weight, incidence of seizures and 72 h mortality were also determined. After Nissl staining and TUNEL in coronal brain sections, the numbers of intact and damaged cells were counted in the CA1 sector of the hippocampus. The expression of phosphorylated inhibitor of kappaB (p-IkappaBalpha), nuclear factor-kappaB (NF-kappaB) subunit p65, and cyclo-oxygenase-2 (COX-2) were analyzed with Western blot at 12 h after reperfusion. GW3965 tended to reduce 72 h mortality and the incidence of post-ischemic seizures. GW3965-treated rats showed an improved neuronal survivability in CA1 and a significant increase in the percentage of spontaneous alternations detected in T-maze on day 7 after ischemia. GW3965-induced neuroprotection was associated with a significant reduction in nuclear translocation of NF-kB p65 subunit and a decrease in the hippocampal expression of NF-kB target gene, COX-2. LXR receptor agonist protects against neuronal damage following global cerebral ischemia. The mechanism of neuroprotection may include blockade of NF-kappaB activation and the subsequent suppression of COX-2 in the post ischemic brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.